Getlabs is a technology company.
Getlabs has raised $23.0M across 2 funding rounds.
Getlabs has raised $23.0M in total across 2 funding rounds.
Getlabs has raised $23.0M in total across 2 funding rounds.
Getlabs's investors include Ambridge Capital, Audrey Capital, Blockchain Founders Fund, Casa Verde Capital, Comal Ventures, Jazz Venture Partners, Montauk Ventures, NEO, Pareto Holdings, Wealthing VC Club, George Morrison, Mathieu Guerville.
# Getlabs: At-Home Diagnostics for the Telehealth Era
Getlabs is a healthcare technology platform that brings laboratory testing into patients' homes, solving a critical gap in telehealth delivery.[1] Founded in 2018, the company dispatches mobile phlebotomists to collect diagnostic samples from patients at home and delivers them to major laboratories like Labcorp and Quest for processing.[1] The platform serves healthcare organizations, providers, and individual patients by removing barriers to diagnostic testing—addressing the fact that clinician-ordered lab testing informs 70% of medical decisions, yet most telehealth experiences still require patients to visit physical locations for blood work and imaging.[2]
Getlabs has scaled rapidly from a Phoenix-based startup to covering over 64% of the U.S. population across 45 markets.[2] The company has raised $41.69M in Series A-II funding, with its most recent raise of $18.69M occurring two years ago.[1] Its mission centers on expanding access to diagnostics for everyone through convenient, at-home services that maintain the highest standards of care.
Getlabs was founded in 2018 by Kyle Michelson, who began with a straightforward vision: making diagnostics as accessible as a patient's front door.[2] In the early days, Michelson reached out directly to leaders at major diagnostic companies to understand what infrastructure and partnerships would be needed to execute this vision.[2] This founder-led approach to understanding market needs—rather than building in isolation—shaped the company's early strategy of partnering with established laboratory networks rather than competing with them.
The company emerged at a pivotal moment when telehealth adoption was accelerating, yet a fundamental limitation persisted: patients still had to leave their homes for lab work, breaking the promise of fully remote healthcare. Getlabs identified and filled this gap, achieving significant traction by securing investment from Labcorp itself in 2022, validating both the business model and the strategic importance of the service to the diagnostic industry.[2]
Getlabs operates at the intersection of two powerful healthcare trends: the explosive growth of telehealth and the increasing demand for home-based care delivery. The company is riding the wave of virtual care adoption, which exploded during the pandemic and has remained elevated, yet it solves a real constraint that telehealth platforms face—the inability to complete the full diagnostic journey remotely.
The timing is particularly favorable because healthcare systems are under pressure to improve patient adherence, reduce no-show rates, and lower operational costs. By bringing phlebotomy to patients rather than requiring patients to travel, Getlabs directly addresses these pain points while enabling providers to offer a genuinely seamless telehealth experience. The company's partnerships with industry giants like Labcorp signal that established diagnostic players recognize at-home collection as a strategic necessity rather than a threat.
Getlabs also influences the broader ecosystem by demonstrating a viable model for healthcare technology: partnering with incumbents rather than disrupting them, focusing on a specific operational bottleneck, and scaling through platform integration rather than vertical integration.
Getlabs has positioned itself as essential infrastructure for the telehealth economy. As remote care becomes the default for routine consultations and chronic disease management, the ability to complete lab work without leaving home will shift from a convenience feature to a baseline expectation. The company's growth trajectory—from startup to 64% U.S. coverage in under a decade—suggests strong market validation.
Looking ahead, Getlabs' influence will likely expand as healthcare organizations increasingly embed at-home diagnostics into their care pathways. Partnerships like the one with Inocras (for whole genome sequencing) hint at a future where Getlabs becomes the logistics backbone for increasingly sophisticated home-based testing, including advanced diagnostics beyond traditional blood work.[1] The key question is whether the company can maintain its growth rate while managing the operational complexity of coordinating phlebotomists across diverse markets—a challenge that will define whether Getlabs becomes a category-defining platform or remains a valuable but niche service.
Getlabs has raised $23.0M across 2 funding rounds. Most recently, it raised $20.0M Series A in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $20.0M Series A | Ambridge Capital, Audrey Capital, Blockchain Founders Fund, Casa Verde Capital, Comal Ventures, Jazz Venture Partners, Montauk Ventures, NEO, Pareto Holdings, Wealthing VC Club, George Morrison, Mathieu Guerville, Troy Carter | |
| Aug 1, 2020 | $3.0M Seed | Andreessen Horowitz, LAUNCH, PivotNorth Capital, Sound Ventures, Uncork Capital, Uprising, Steve Krausz, Jim Pitkow, Kurt Bilafer, Stephen Garden |